메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

An Era Where Meditation Becomes a Quantifiable Achievement -- Japan's First "Quantified Meditation Challenge"

TOKYO, Oct. 7, 2025 -- Meditation entered a new era as the World Meditation League (WML), and All Here introduced Japan's first Tokyo Quantified Meditation Challenge in the gardens of Happo-en. This unprecedented event took meditation beyond personal introspection — transforming it into a measurable, observable, and competitive discipline through neuroscience. For the first time, audiences witnessed meditation in real time, as brain activity, attention, self-awareness and inner silence were displayed as quantifiable data on screen. Technology × Archi
- 김갑성 기자
- 2025-10-07 21:24
Metabolon's Metabolomics Services Now Cited in More Than 4,000 Peer-Reviewed Publications

Metabolon's best-in-class metabolomics leadership accelerates as metabolomics becomes a standard inclusion in global multiomics studies MORRISVILLE, N.C., Oct. 7, 2025 -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced that its metabolomics services have now been cited in more than 4,000 peer-reviewed publications, far more than any other metabolomics provider in the life sciences industry. Publications refer
- 김갑성 기자
- 2025-10-07 21:00
ZEISS expands DORC portfolio and further strengthens digital footprint with improved workflow efficiency and digital visualization

Showcasing at AAO 2025: NEW 510k CLEARANCE SUPPORTS MORE INFORMED DECISION MAKING & PATHOLOGY DETECTION: Showcasing optical coherence tomography angiography (OCT-A) with ZEISS CIRRUS AngioPlex® with noninvasive imaging of the retinal and choroidal vasculature; now with 510k clearance and CE approval, ICGA for CLARUS® 700 offers FA + ICG simultaneous capture. OPTIMIZED RETINAL SURGICAL EXPERIENCE: Announcing updates to DORC instruments to expand surgeons' options, including new gauges added to the range of subretinal injection cannulae and a new Midfield endoillu
- 김갑성 기자
- 2025-10-07 21:00
Celaid Therapeutics Raises JPY 1.055 Billion (USD 7.2 Million) in the First Close of its Series B Financing

TOKYO, Oct. 7, 2025 -- Celaid Therapeutics Inc. ("Celaid"), today announced the successful completion of the 1st Close of its Series B financing round, raising JPY 1.055 billion (USD 7.2 million) from venture capital firms and the Japan Agency for Medical Research and Development (AMED). Including grants and subsidies, Celaid's cumulative funding has reached JPY 2.52 billion (USD 17.14 million). This financing reflects recognition of the progress in the company's lead pipeline program CLD-001, a novel ex vivo-expanded hematopoietic stem cell (HSC) therapy for severe pediatric
- 김갑성 기자
- 2025-10-07 21:00
Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program

SYDNEY, Oct. 7, 2025 -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced an exclusive collaboration and in-licensing agreement (the "Agreement") with QIMR Berghofer for a first-in-class PD-L1 degrader program. The lead optimized compound, NDL2, is an advanced PD-L1 protein degrader currently in development and represents a new and innovative frontier of cancer immunotherapy. About PD-L1 Degradation and NDL2 Cancer cells frequently express PD-L1 protein to evade immune attack. When PD-L1 on a tumor cell surface bin
- 김갑성 기자
- 2025-10-07 20:30
Pantai Hospital Kuala Lumpur at Kuala Lumpur Standard Chartered Marathon 2025

[ 메디채널 김갑성 기자 ] From preventive screenings to Medic-On-The-Run, Pantai Hospital Kuala Lumpur brings healthcare beyond the hospital for Generation after Generation. KUALA LUMPUR, Malaysia, Oct. 7, 2025 -- Health, like running, is a journey, not a destination. As Malaysia's runners pushed their limits at the Kuala Lumpur Standard Chartered Marathon (KLSCM) 2025, Pantai Hospital Kuala Lumpur (PHKL) ran with them, not just as medical support, but as a legacy partner in wellness, carrying its mission of care from one generation to the next. This year, a record-breaking 42,000 participants
- 김갑성 기자
- 2025-10-07 17:19
Milliken & Company Launches Millad ClearX™ 9000: The Clear Choice for Polypropylene

Delivers exceptional clarity with lower additive levels, streamlining production and expanding formulation options for converters and resin producers SPARTANBURG, S.C., Oct. 7, 2025 -- Milliken & Company proudly announces the launch of Millad ClearX™ 9000, the next generation clarifying technology for polypropylene (PP) developed to deliver ultra-clear transparency at reduced additive loading levels. Ideal for food packaging, home storage, and medical applications, Millad ClearX™ 9000 sets a new standard for value, aesthetics, and operational efficiency in transparent PP ap
- 김갑성 기자
- 2025-10-07 13:48
Kadisco General Hospital and MindHYVE.ai™ Sign Strategic MoU to Transform Healthcare in Ethiopia with Agentic AI

ADDIS ABABA, Ethiopia, Oct. 7, 2025 -- Kadisco General Hospital (KGH), one of Ethiopia's leading private healthcare institutions, and MindHYVE.ai™, a U.S.-based pioneer in agentic artificial intelligence (AI), have signed a Memorandum of Understanding (MoU) to launch an ambitious collaboration that will accelerate AI-powered healthcare innovation, operational efficiency, and workforce capacity-building in Ethiopia. The partnership, formalized in Addis Ababa on September 11, 2025, brings together Kadisco's strong foundation in clinical excellence with MindHYVE.ai's™ adva
- 김갑성 기자
- 2025-10-07 13:33
Terumo Blood and Cell Technologies Honored with Corporate Excellence Award at the Asia Pacific Enterprise Awards 2025 Regional Edition

SINGAPORE, Oct. 7, 2025 -- Terumo Blood and Cell Technologies (Terumo BCT) has been recognized with the Corporate Excellence Award at the Asia Pacific Enterprise Awards (APEA) 2025 Regional Edition organized by Enterprise Asia, a testament to its unwavering commitment to innovation, patient care, and global healthcare advancement. Serving customers in more than 160 countries, Terumo BCT empowers blood and cell-based therapies that improve patient outcomes and address unmet medical needs. With 7,900 associates and over 400 distributors, the company maintains a strong global presence spa
- 김갑성 기자
- 2025-10-07 13:25
Japanese Innovation Comes to Thailand: Revolutionary Myopia Management Device Kubota Glass Debuts at ASEAN International Optics Fair Bangkok 2025

TOKYO, Oct. 7, 2025 -- Leading Japanese pharmaceutical company Kubota Pharmaceutical Holdings Co., Ltd. will introduce Thailand to its groundbreaking myopia management device, Kubota Glass, at Bangkok. Addressing Thailand's Growing Myopia Crisis Thailand is facing a growing myopia challenge, with studies reporting that over 60%* of young adults are already myopic—among the highest rates observed in Southeast Asia. This pattern reflects the wider regional concern, where nearly half of the world's population is projected to be myopic by 2050. "Thai families are
- 김갑성 기자
- 2025-10-07 11:00

이전

31 32 33 34 35 36 37 38 39 40

많이 본 기사

최근기사

2025-11-04_TUE

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 05일 00시 00분